Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation

Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism for its action is that it prevents the proteasomal degradation of proapoptotic proteins, leading to enhanced apoptosis. Although...

Full description

Bibliographic Details
Main Authors: Abd Aziz, Noraini, Stanbridge, Eric J., Shafee, Norazizah
Format: Article
Language:English
Published: Spandidos Publications 2015
Online Access:http://psasir.upm.edu.my/id/eprint/36675/
http://psasir.upm.edu.my/id/eprint/36675/1/Bortezomib%20attenuates%20HIF-1-%20but%20not%20HIF-2-mediated%20transcriptional%20activation.pdf
_version_ 1848848398618198016
author Abd Aziz, Noraini
Stanbridge, Eric J.
Shafee, Norazizah
author_facet Abd Aziz, Noraini
Stanbridge, Eric J.
Shafee, Norazizah
author_sort Abd Aziz, Noraini
building UPM Institutional Repository
collection Online Access
description Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism for its action is that it prevents the proteasomal degradation of proapoptotic proteins, leading to enhanced apoptosis. Although the α subunit of hypoxia‑inducible factor (HIF)‑1 is not degraded with bortezomib treatment, the heterodimeric HIF‑1 fails to transactivate target genes. HIF‑1 and HIF‑2 are related hypoxia‑inducible transcription factors that are important for the survival of hypoxic tumor cells. The majority of reports have focused on the effects of bortezomib on the transcriptional activities of HIF‑1, but not HIF‑2. The present study investigated the effects of bortezomib on HIF‑2 activity in cancer cells with different levels of HIF‑1α and HIF‑2α subunits. HIF‑α subunit levels were detected using specific antibodies, while HIF transcriptional activities were evaluated using immunodetection, reverse transcription‑polymerase chain reaction and luciferase reporter assay. Bortezomib treatment was found to suppress the transcription and expression of CA9, a HIF‑1‑specific target gene; however, it had minimal effects on EPO and GLUT‑1, which are target genes of both HIF‑1 and HIF‑2. These data suggest that bortezomib attenuates the transcriptional activity only of HIF‑1, and not HIF‑2. This novel finding on the lack of an inhibitory effect of bortezomib on HIF‑2 transcriptional activity has implications for the improvement of design and treatment modalities of bortezomib and other PI drugs.
first_indexed 2025-11-15T09:33:52Z
format Article
id upm-36675
institution Universiti Putra Malaysia
institution_category Local University
language English
last_indexed 2025-11-15T09:33:52Z
publishDate 2015
publisher Spandidos Publications
recordtype eprints
repository_type Digital Repository
spelling upm-366752020-07-06T03:12:39Z http://psasir.upm.edu.my/id/eprint/36675/ Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation Abd Aziz, Noraini Stanbridge, Eric J. Shafee, Norazizah Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism for its action is that it prevents the proteasomal degradation of proapoptotic proteins, leading to enhanced apoptosis. Although the α subunit of hypoxia‑inducible factor (HIF)‑1 is not degraded with bortezomib treatment, the heterodimeric HIF‑1 fails to transactivate target genes. HIF‑1 and HIF‑2 are related hypoxia‑inducible transcription factors that are important for the survival of hypoxic tumor cells. The majority of reports have focused on the effects of bortezomib on the transcriptional activities of HIF‑1, but not HIF‑2. The present study investigated the effects of bortezomib on HIF‑2 activity in cancer cells with different levels of HIF‑1α and HIF‑2α subunits. HIF‑α subunit levels were detected using specific antibodies, while HIF transcriptional activities were evaluated using immunodetection, reverse transcription‑polymerase chain reaction and luciferase reporter assay. Bortezomib treatment was found to suppress the transcription and expression of CA9, a HIF‑1‑specific target gene; however, it had minimal effects on EPO and GLUT‑1, which are target genes of both HIF‑1 and HIF‑2. These data suggest that bortezomib attenuates the transcriptional activity only of HIF‑1, and not HIF‑2. This novel finding on the lack of an inhibitory effect of bortezomib on HIF‑2 transcriptional activity has implications for the improvement of design and treatment modalities of bortezomib and other PI drugs. Spandidos Publications 2015 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/36675/1/Bortezomib%20attenuates%20HIF-1-%20but%20not%20HIF-2-mediated%20transcriptional%20activation.pdf Abd Aziz, Noraini and Stanbridge, Eric J. and Shafee, Norazizah (2015) Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation. Oncology Letters, 10 (4). pp. 2192-2196. ISSN 1792-1074; ESSN: 1792-1082 https://www.spandidos-publications.com/10.3892/ol.2015.3545/abstract 10.3892/ol.2015.3545
spellingShingle Abd Aziz, Noraini
Stanbridge, Eric J.
Shafee, Norazizah
Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation
title Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation
title_full Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation
title_fullStr Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation
title_full_unstemmed Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation
title_short Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation
title_sort bortezomib attenuates hif-1- but not hif-2-mediated transcriptional activation
url http://psasir.upm.edu.my/id/eprint/36675/
http://psasir.upm.edu.my/id/eprint/36675/
http://psasir.upm.edu.my/id/eprint/36675/
http://psasir.upm.edu.my/id/eprint/36675/1/Bortezomib%20attenuates%20HIF-1-%20but%20not%20HIF-2-mediated%20transcriptional%20activation.pdf